01 9Xeljanz
02 1Xeljianz
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 2,242
2018 Revenue in Millions : 1,774
Growth (%) : 26
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 2,437
2019 Revenue in Millions : 2,242
Growth (%) : 9
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 2,455
2020 Revenue in Millions : 2,437
Growth (%) : 1
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 1,796
2021 Revenue in Millions : 2,455
Growth (%) : -27
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 1,703
2022 Revenue in Millions : 1,796
Growth (%) : -5
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2015 Revenue in Millions : 308
2014 Revenue in Millions : 523
Growth (%) : 70%
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2014 Revenue in Millions : 170.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2016 Revenue in Millions : 927
2015 Revenue in Millions : 524
Growth (%) : 77
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2017 Revenue in Millions : 1,345
2016 Revenue in Millions : 927
Growth (%) : 45
Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...
Currency : USD
2018 Revenue in Millions : 1,773
2017 Revenue in Millions : 1,345
Growth (%) : 32%
LOOKING FOR A SUPPLIER?